Home » FDA Grants Astellas Fast Track Designation for Peanut Allergy Vaccine
FDA Grants Astellas Fast Track Designation for Peanut Allergy Vaccine
January 6, 2017
Tokyo-based Astellas has received an FDA Fast Track designation for ASP0892, to reduce or eliminate sensitivity to the three major peanut allergens.
ASP0892 is a part of a new DNA vaccine program designed to stimulate an immune response against a particular protein. The company has launched a Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts.
In October 2015, Astellas and Immunomic Therapeutics entered into an agreement to co-develop products for the treatment or prevention of any and all human allergic diseases.
Upcoming Events
-
21Oct